Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
Conditions Studied
Interventions
- DRUG TUB-030
Study Locations (16)
Other
- Princess Margaret — Toronto
- Arensia Exploratory Medicine — Bucharest
- Arensia Exploratory Medicine — Cluj-Napoca
- Clinica Uni de Navara — Madrid
Texas
- NEXT Oncology Austin — Austin
- NEXT Oncology - Dallas — Irving
- NEXT Oncology - San Antonio — San Antonio
Ohio
- Cleveland Clinic — Cleveland
- Ohio State University — Columbus
Connecticut
- Yale Cancer Center — New Haven
Florida
- University of Miami — Miami
Massachusetts
- Dana Farber Cancer Institute — Boston
Minnesota
- Mayo Clinic — Rochester
Missouri
- Washington University — St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06657222
The ClinicalTrials.gov registry entry for NCT06657222 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tubulis, which has 33 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 6 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention — of which TUB-030 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06657222 reports 16 study locations spanning 10 distinct geographic areas — top geographies include Other, Texas, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06657222 about?
NCT06657222 is a clinical study titled "First in Human Study of TUB-030 in Patients With Advanced Solid Tumors". The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 ...
What is the current status of trial NCT06657222?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2024-12-13. Estimated completion is 2028-12.
What conditions does trial NCT06657222 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, NSCLC, HNSCC, TNBC - Triple-Negative Breast Cancer, CRC. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06657222?
The interventions under investigation include: TUB-030 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06657222?
This trial is sponsored by Tubulis, which has 33 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06657222 being conducted?
This trial has 16 study locations across Connecticut, Florida, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.